BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received its first patent related to the ability of its lead drug candidate, Thymosin beta 4 (Tß4), to prevent damage and promote healing associated with myocardial events, including heart attack, vessel occlusion and heart valve damage, among others. The Australian patent includes Tß4, analogues, fragments and other derivatives, methods of use and delivery, either independently or in combination with other agents. Similar patent applications have been submitted throughout the world. On March 30, 2007, RegeneRx filed an Investigational New Drug application (IND) to initiate a Phase 1 trial in support of this indication.
